MCID: SKN019
MIFTS: 61

Skin Melanoma

Categories: Cancer diseases, Skin diseases, Ear diseases

Aliases & Classifications for Skin Melanoma

MalaCards integrated aliases for Skin Melanoma:

Name: Skin Melanoma 12 52 14
Cutaneous Melanoma 12 29 69
Malignant Melanoma of Ear and/or External Auricular Canal 12
Malignant Melanoma of Skin of Trunk Except Scrotum 12
Malignant Melanoma of Skin of Lower Limb 12
Malignant Melanoma of Skin of Upper Limb 12
Malignant Lower Limb Melanoma 12
Malignant Upper Limb Melanoma 12
Melanoma, Cutaneous Malignant 42
Malignant Scalp Melanoma 12
Malignant Trunk Melanoma 12
Malignant Neck Melanoma 12
Malignant Ear Melanoma 12
Malignant Lip Melanoma 12
Melanoma 69

Classifications:



Summaries for Skin Melanoma

Disease Ontology : 12 A skin cancer that has material basis in melanocytes.

MalaCards based summary : Skin Melanoma, also known as cutaneous melanoma, is related to melanoma, cutaneous malignant 8 and melanoma, cutaneous malignant, 9, and has symptoms including exanthema and pruritus. An important gene associated with Skin Melanoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Mekinist and Aldesleukin have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and kidney, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and homeostasis/metabolism

Related Diseases for Skin Melanoma

Diseases related to Skin Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 169)
id Related Disease Score Top Affiliating Genes
1 melanoma, cutaneous malignant 8 12.3
2 melanoma, cutaneous malignant, 9 12.3
3 melanoma, cutaneous malignant, 2 12.3
4 melanoma, cutaneous malignant, 3 12.3
5 melanoma, cutaneous malignant, 6 12.3
6 melanoma, cutaneous malignant, 5 12.3
7 melanoma, cutaneous malignant 10 12.2
8 superficial spreading melanoma 11.2
9 mitf-related susceptibility to cutaneous malignant melanoma 11.1
10 pot1-related susceptibility to cutaneous malignant melanoma 11.1
11 tumor predisposition syndrome 11.0
12 cervical adenoid cystic carcinoma 10.9 CDKN2A TP53
13 acral lentiginous melanoma 10.9
14 tietz albinism-deafness syndrome 10.9 MITF TYR
15 malignant melanoma, somatic 10.8
16 mirror polydactyly-vertebral segmentation-limbs defects syndrome 10.8 BRAF TP53
17 raf1-related noonan syndrome 10.8 BRAF NRAS
18 endocervical type cervical adenomyoma 10.8 MITF PMEL
19 rnase t2-deficient leukoencephalopathy 10.8 MDM2 TP53
20 commad syndrome 10.8 MITF TYR
21 penis paget's disease 10.8 CDKN2A CDKN2B TP53
22 pilocytic astrocytoma of cerebellum 10.7 BRAF TP53
23 olfactory neural tumor 10.7 CDKN2A NRAS TP53
24 hanhart syndrome 10.7 PMEL TYR
25 vulval paget's disease 10.7 CDKN2A NRAS TYR
26 split hand split foot nystagmus 10.7 BRAF CDKN2A TP53
27 preeclampsia/eclampsia 3 10.6 CDKN2A CDKN2B TP53
28 secondary pulmonary hemosiderosis 10.6 CDKN2A MDM2 TP53
29 autism susceptibility 16 10.6 MITF PMEL TYR
30 bladder squamous cell carcinoma 10.6 CDKN2A MDM2 TP53
31 c-p angle neurinoma 10.6 CDKN2A MDM2 TP53
32 parotid gland adenoid cystic carcinoma 10.6 BRAF MITF NRAS
33 ascaridiasis 10.6 MDM2 NRAS TP53
34 pancreatoblastoma 10.6 CDKN2A FGF2 TP53
35 melanoma 10.6
36 rhizomelic chondrodysplasia punctata, type 3 10.6 CASP3 TP53
37 non-distal trisomy 10q 10.5 BRAF NRAS TP53
38 facial arteriovenous malformation 10.5 MMP2 MMP9
39 juvenile astrocytoma 10.5 BRAF MDM2 TP53
40 accessory nerve disease 10.5 CDKN2A MDM2 TP53
41 acute cholinergic dysautonomia 10.5 CDKN1A MDM2 TP53
42 tropical spastic paraparesis 10.5 PMEL TYR
43 integumentary system cancer 10.5 CASP3 CDKN2A TP53
44 familial short qt syndrome 10.5 MMP2 MMP9
45 bone marrow cancer 10.5 CDKN2A NRAS PMEL TYR
46 skin amelanotic melanoma 10.5 CDKN1A CDKN2A MMP2
47 tenosynovitis of foot and ankle 10.5 CDKN1A MMP2 TP53
48 tendon sheath lipoma 10.5 PTGS2 TP53
49 lung clear cell-sugar-tumor 10.5 CDKN1A MDM2 TP53
50 fallopian tube serous papilloma 10.5 MITF NRAS PMEL TYR

Graphical network of the top 20 diseases related to Skin Melanoma:



Diseases related to Skin Melanoma

Symptoms & Phenotypes for Skin Melanoma

UMLS symptoms related to Skin Melanoma:


exanthema, pruritus

GenomeRNAi Phenotypes related to Skin Melanoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 CASP3 CDKN1A CDKN2A MLH1 PMEL TP53
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 BRAF CASP3 CDKN1A CDKN2A MLH1 PMEL

MGI Mouse Phenotypes related to Skin Melanoma:

44 (show all 26)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.49 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
2 cellular MP:0005384 10.46 NRAS PTGS2 TP53 TYR BRAF CASP3
3 behavior/neurological MP:0005386 10.44 CASP3 CDKN1A CDKN2A FGF2 MCAM MDM2
4 cardiovascular system MP:0005385 10.44 NRAS PTGS2 TP53 TYR BRAF CASP3
5 endocrine/exocrine gland MP:0005379 10.44 TP53 TYR MDM2 MIA MITF MLH1
6 hematopoietic system MP:0005397 10.44 MMP2 MMP9 NRAS PMEL PTGS2 TP53
7 integument MP:0010771 10.44 MITF MLH1 MMP9 NME1 NRAS PMEL
8 growth/size/body region MP:0005378 10.4 MMP9 NME1 NRAS PTGS2 TP53 TYR
9 mortality/aging MP:0010768 10.4 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
10 immune system MP:0005387 10.39 BRAF CASP3 CDKN1A CDKN2A CDKN2B MCAM
11 digestive/alimentary MP:0005381 10.3 BRAF CASP3 CDKN1A CDKN2A MDM2 MLH1
12 neoplasm MP:0002006 10.3 BRAF CDKN1A CDKN2A CDKN2B FGF2 MDM2
13 craniofacial MP:0005382 10.26 MITF MMP2 NRAS TP53 TYR BRAF
14 embryo MP:0005380 10.25 TP53 TYR BRAF CDKN1A CDKN2A MDM2
15 nervous system MP:0003631 10.25 PTGS2 TP53 TYR BRAF CASP3 CDKN1A
16 muscle MP:0005369 10.18 BRAF CASP3 CDKN1A CDKN2A FGF2 MDM2
17 no phenotypic analysis MP:0003012 10.18 CASP3 CDKN1A CDKN2A CDKN2B MCAM MDM2
18 hearing/vestibular/ear MP:0005377 10.12 BRAF CASP3 CDKN1A FGF2 MITF TP53
19 liver/biliary system MP:0005370 10.11 BRAF CDKN1A CDKN2A MDM2 NME1 NRAS
20 limbs/digits/tail MP:0005371 10.07 CDKN1A MDM2 MITF MMP9 NRAS TP53
21 reproductive system MP:0005389 10.07 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
22 pigmentation MP:0001186 10.02 PMEL TP53 TYR BRAF CASP3 CDKN2A
23 renal/urinary system MP:0005367 9.97 BRAF CASP3 CDKN1A CDKN2B MDM2 MMP9
24 respiratory system MP:0005388 9.81 BRAF CASP3 CDKN1A CDKN2A MLH1 MMP2
25 skeleton MP:0005390 9.77 MMP9 PTGS2 TP53 TYR BRAF CASP3
26 vision/eye MP:0005391 9.47 BRAF CASP3 CDKN1A CDKN2A FGF2 MITF

Drugs & Therapeutics for Skin Melanoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Mekinist 17 46 TRAMETINIB DIMETHYL SULFOXIDE GlaxoSmithKline May of 2013

Drugs for Skin Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 277)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85898-30-2, 110942-02-4
2
Etanercept Approved, Investigational Phase 4 185243-69-0
3
Aminolevulinic acid Approved Phase 4,Phase 2 106-60-5 137
4 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
5 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
6 Antirheumatic Agents Phase 4,Phase 2,Phase 1,Early Phase 1
7 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
8 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
9 Dermatologic Agents Phase 4,Phase 1,Phase 2
10 Interleukin-2 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
11 Anti-Inflammatory Agents Phase 4,Phase 2
12 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
13 Gastrointestinal Agents Phase 4,Phase 1,Phase 2
14 Photosensitizing Agents Phase 4,Phase 1,Phase 2
15
Peginterferon alfa-2b Approved Phase 3,Phase 2,Phase 1 99210-65-8, 215647-85-1
16
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
17
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
18
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
19
Sorafenib Approved, Investigational Phase 3,Phase 1,Phase 2 284461-73-0 216239 406563
20
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
21
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 4342-03-4 5351166
22
Lenograstim Approved Phase 3,Phase 1,Phase 2 135968-09-1
23
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1 85622-93-1 5394
24
Imiquimod Approved, Investigational Phase 3,Phase 1,Phase 2,Early Phase 1 99011-02-6 57469
25
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
26
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 4053 460612
27
Trametinib Approved Phase 3,Phase 2,Phase 1 871700-17-3 11707110
28
Vinblastine Approved Phase 3,Phase 1,Phase 2 865-21-4 13342 241903
29
Peginterferon alfa-2a Approved, Investigational Phase 3 198153-51-4 5360545
30
Dabrafenib Approved Phase 3,Phase 2,Phase 1 44462760 44516822
31
Pembrolizumab Approved Phase 3,Phase 1,Phase 2,Early Phase 1 1374853-91-4
32
nivolumab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 946414-94-4
33
Propranolol Approved, Investigational Phase 2, Phase 3 525-66-6 4946
34
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
35
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 59-67-6 938
36
Nicotinamide Approved, Nutraceutical Phase 3,Phase 2,Phase 1 98-92-0 936
37
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
38
Cholecalciferol Approved, Nutraceutical Phase 3 67-97-0 6221 10883523 5280795
39
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
40
BCG vaccine Investigational Phase 2, Phase 3
41 Molgramostim Investigational Phase 2, Phase 3 99283-10-0
42 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1,Early Phase 1
43
QS 21 Phase 3,Phase 2,Phase 1 141256-04-4
44 Vaccines Phase 3,Phase 2,Phase 1,Early Phase 1
45 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
46 Antiviral Agents Phase 3,Phase 2,Phase 1
47 Interferon-alpha Phase 3,Phase 2,Phase 1
48 interferons Phase 3,Phase 2,Phase 1,Early Phase 1
49 Detox adjuvant Phase 3,Phase 1,Phase 2
50 Anti-HIV Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 630)

id Name Status NCT ID Phase Drugs
1 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
2 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Recruiting NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
3 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
4 Vaccine Therapy in Treating Patients With Primary Stage II Melanoma Unknown status NCT00005052 Phase 3
5 Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00006249 Phase 3
6 Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma Unknown status NCT00002767 Phase 3
7 High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00002763 Phase 3
8 Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver Unknown status NCT00039234 Phase 3 histamine dihydrochloride
9 Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma Unknown status NCT00002455 Phase 3
10 Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin Completed NCT00003444 Phase 3
11 Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma Completed NCT00324727 Phase 3 melphalan;regional chemotherapy;systemic chemotherapy
12 PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial) Completed NCT00221702 Phase 3 PegIntron;intron A
13 Sargramostim and/or Vaccine Therapy in Preventing Disease Recurrence in Patients With Advanced Melanoma Completed NCT01989572 Phase 3
14 Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma Completed NCT00019682 Phase 3 Montanide ISA 51 VG
15 GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma Completed NCT01245062 Phase 3 GSK1120212;Chemotherapy
16 Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Completed NCT00110019 Phase 3 Carboplatin;Paclitaxel;Sorafenib Tosylate
17 Evaluation of Pigmented Skin Lesions With MelaFind(R) System Completed NCT00434057 Phase 3
18 Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma Completed NCT00002882 Phase 3 Cisplatin;Dacarbazine;Vinblastine
19 Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma Completed NCT00072124 Phase 3 cisplatin;dacarbazine
20 Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma Completed NCT00003027 Phase 3 cisplatin;dacarbazine;vinblastine
21 S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma Completed NCT00006237 Phase 3 cisplatin;dacarbazine;vinblastine
22 Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent Melanoma Completed NCT00002892 Phase 3
23 Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis Completed NCT00004196 Phase 3 Observation
24 Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma Completed NCT00016263 Phase 3 dacarbazine
25 Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma Completed NCT00039000 Phase 3 HSPPC-96 or Oncophage
26 Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB Completed NCT00204529 Phase 3 pegylated interferon-alpha-2a;interferon-alpha-2a
27 MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma Completed NCT00094653 Phase 3 MDX-010 (anti-CTLA4) monoclonal antibody
28 An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma Completed NCT01368276 Phase 3 Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)
29 Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome Recruiting NCT01748448 Phase 3 Vitamin D;arachides oleum raffinatum
30 PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma Recruiting NCT02288897 Phase 3 PV-10 (10% rose bengal disodium);Dacarbazine, temozolomide or talimogene laherparepvec
31 MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma Recruiting NCT02385214 Phase 3
32 Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients Recruiting NCT01729663 Phase 2, Phase 3 interferon alpha 2b
33 Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma Recruiting NCT02224781 Phase 3 Dabrafenib;Trametinib
34 Melanoma Patients Immunized With Natural DenDritic Cells Recruiting NCT02993315 Phase 3
35 Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face Recruiting NCT01720407 Phase 3 Imiquimod cream + surgery;Placebo + surgery
36 Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma Active, not recruiting NCT01597908 Phase 3 Dabrafenib;Vemurafenib;Trametinib
37 Adjuvant PEG Intron in Ulcerated Melanoma Active, not recruiting NCT01502696 Phase 3
38 A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma Active, not recruiting NCT01584648 Phase 3 dabrafenib;dabrafenib plus trametinib placebo;Trametinib
39 Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Active, not recruiting NCT01763164 Phase 3 MEK162;Dacarbazine
40 Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Active, not recruiting NCT01274338 Phase 3
41 A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection. Active, not recruiting NCT01682083 Phase 3 Dabrafenib;Trametinib;Placebos
42 A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma Active, not recruiting NCT01667419 Phase 3 Vemurafenib;Placebo
43 High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Active, not recruiting NCT02506153 Phase 3
44 Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Active, not recruiting NCT01909453 Phase 3 LGX818;MEK162;vemurafenib
45 MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients Not yet recruiting NCT02962947 Phase 2, Phase 3 Propranolol;Placebo
46 SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer Not yet recruiting NCT03294330 Phase 3 IC-Green KIT
47 M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma Not yet recruiting NCT00477906 Phase 3
48 Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Suspended NCT02339571 Phase 2, Phase 3
49 High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma Terminated NCT00003641 Phase 3
50 Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain Terminated NCT00020839 Phase 3 temozolomide

Search NIH Clinical Center for Skin Melanoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: melanoma, cutaneous malignant

Genetic Tests for Skin Melanoma

Genetic tests related to Skin Melanoma:

id Genetic test Affiliating Genes
1 Cutaneous Melanoma 29

Anatomical Context for Skin Melanoma

MalaCards organs/tissues related to Skin Melanoma:

39
Skin, Lymph Node, Kidney, Brain, Lung, Liver, T Cells

Publications for Skin Melanoma

Articles related to Skin Melanoma:

(show top 50) (show all 143)
id Title Authors Year
1
Incidence trends and survival of skin melanoma and squamous cell carcinoma in Cluj County, Romania. ( 28914690 )
2017
2
Seasonality of birth for skin melanoma deserves further investigation. ( 28338933 )
2017
3
Review and proposal of regional surgical management for melanoma: revisiting of integumentectomy and incontinuity dissection in treatment of skin melanoma. ( 28064397 )
2017
4
Reply to: Seasonality of birth for skin melanoma deserves further investigation. ( 28338928 )
2017
5
Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma. ( 28092675 )
2017
6
Metallic copper nanoparticle induces apoptosis in human skin melanoma, A-375 cell line. ( 28067213 )
2017
7
Health and Economic Burden of Skin Melanoma in Croatia - Cost-of-illness Study. ( 28511743 )
2017
8
Molecular Biology and Genetic Mechanisms in the Progression of the Malignant Skin Melanoma. ( 27883322 )
2016
9
Prognostic significance of immunohistochemical epithelial-mesenchymal transition markers in skin melanoma patients. ( 27586584 )
2016
10
Fasting boosts sensitivity of human skin melanoma to cisplatin-induced cell death. ( 27693581 )
2016
11
Expression of Molecular Markers of Angiogenesis, Lymphangiogenesis, and Proliferation Depending on the Stage of Skin Melanoma. ( 27590758 )
2016
12
A case report of gastroduodenal metastasis from skin melanoma. ( 27264432 )
2016
13
Anticancer properties of phospholipase A2 from Daboia siamensis venom on human skin melanoma cells. ( 26884744 )
2016
14
Demodex Mite, Rosacea and Skin Melanoma; Coincidence or Association? ( 25917583 )
2015
15
Bringing Down Cancer Aircraft: Searching for Essential Hypomutated Proteins in Skin Melanoma. ( 26565620 )
2015
16
Evaluation of chemopreventive potentials of ethanolic extract of Ruta graveolens against A375 skin melanoma cells in vitro and induced skin cancer in mice in vivo. ( 25609370 )
2015
17
Treatment Outcome and Prognostic Factors for Malignant Skin Melanoma Treated with Radical Surgery. ( 26320440 )
2015
18
ANTIPROLIFERATIVE EFFECT OF INOSITOL HEXAPHOSPHATE ON HUMAN SKIN MELANOMA CELLS IN VITRO. ( 26665395 )
2015
19
Negative HER2/neu amplification using immunohistochemistry and chromogenic in situ hybridization techniques in skin melanoma cases. ( 25684465 )
2015
20
Survival of patients with skin melanoma in Europe increases further: Results of the EUROCARE-5 study. ( 26421821 )
2015
21
Calotropis procera extract induces apoptosis and cell cycle arrest at G2/M phase in human skin melanoma (SK-MEL-2) cells. ( 25623835 )
2015
22
Ginseng marc-derived low-molecular weight oligosaccharide inhibits the growth of skin melanoma cells via activation of RAW264.7 cells. ( 26548345 )
2015
23
Encapsulation of palladium porphyrin photosensitizer in layered metal oxide nanoparticles for photodynamic therapy against skin melanoma. ( 27877834 )
2015
24
Cerium Oxide Nanoparticles Induce Oxidative Stress and Genotoxicity in Human Skin Melanoma Cells. ( 25395198 )
2014
25
Oleanolic acid isolated from ethanolic extract of Phytolacca decandra induces apoptosis in A375 skin melanoma cells: drug-DNA interaction and signaling cascade. ( 24666676 )
2014
26
Sensitive allele-specific real-time PCR test for mutations in BRAF codon V600 in skin melanoma. ( 24922189 )
2014
27
Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection. ( 24602025 )
2014
28
Ambient UVA-induced expression of p53 and apoptosis in human skin melanoma A375 cell line by quinine. ( 23336807 )
2013
29
Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing. ( 23846221 )
2013
30
Homeopathic mother tincture of Phytolacca decandra induces apoptosis in skin melanoma cells by activating caspase-mediated signaling via reactive oxygen species elevation. ( 23506692 )
2013
31
Induction of oxidative stress, DNA damage, and apoptosis in a malignant human skin melanoma cell line after exposure to zinc oxide nanoparticles. ( 23493450 )
2013
32
Using SEER data to quantify effects of low income neighborhoods on cause specific survival of skin melanoma. ( 23803107 )
2013
33
Graveoline Isolated from Ethanolic Extract of Ruta graveolens Triggers Apoptosis and Autophagy in Skin Melanoma Cells: A Novel Apoptosis-Independent Autophagic Signaling Pathway. ( 24343999 )
2013
34
Strategic formulation of apigenin-loaded PLGA nanoparticles for intracellular trafficking, DNA targeting and improved therapeutic effects in skin melanoma in vitro. ( 24070738 )
2013
35
Ursolic acid differentially modulates apoptosis in skin melanoma and retinal pigment epithelial cells exposed to UV-VIS broadband radiation. ( 24375173 )
2013
36
Analysis of the application of MMP-9 inhibitor in skin melanoma: experimental study. ( 23658876 )
2013
37
Ret transgenic mouse model of spontaneous skin melanoma: focus on regulatory T cells. ( 23560814 )
2013
38
Chemoprevention of skin melanoma: facts and myths. ( 24077511 )
2013
39
Diagnostic value of intraoperative histopathological examination of the sentinel nodes in breast cancer and skin melanoma-Preliminary results of single centre retrospective study. ( 24416560 )
2013
40
Skin melanoma sentinel lymph node biopsy using real-time fluorescence navigation with indocyanine green and indocyanine green with human serum albumin. ( 21923754 )
2012
41
Doppler ultrasound flowmetry predicts 15 year outcome in patients with skin melanoma. ( 23904713 )
2012
42
Optimization of electron paramagnetic resonance imaging for visualization of human skin melanoma in various stages of invasion. ( 22509830 )
2012
43
HOX Gene Aberrant Expression in Skin Melanoma: A Review. ( 23091727 )
2012
44
The role of surgery in the treatment of colorectal metastases from primary skin melanoma. ( 22251405 )
2012
45
Changes in the levels of N-cadherin and PCNA in skin melanoma cells are mediated through matrix metalloproteinase 9. ( 22866313 )
2012
46
Role of ROC1 protein in the control of cyclin D1 protein expression in skin melanomas. ( 21300445 )
2011
47
Towards noncontact skin melanoma selection by multispectral imaging analysis. ( 21721796 )
2011
48
Morphological changes in human skin melanoma treated by high-energy pulsed neodymium laser radiation. ( 21766508 )
2011
49
Sentinel lymph node biopsy in cases of skin melanoma: initial experiences at a center in northeastern Brazil. ( 21603830 )
2011
50
Molecular Network Associated with MITF in Skin Melanoma Development and Progression. ( 22046555 )
2011

Variations for Skin Melanoma

ClinVar genetic disease variations for Skin Melanoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 CDKN2A NM_000077.4(CDKN2A): c.301G> T (p.Gly101Trp) single nucleotide variant Pathogenic,risk factor rs104894094 GRCh37 Chromosome 9, 21971057: 21971057

Cosmic variations for Skin Melanoma:

9 (show top 50) (show all 1865)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM1176879 TRRAP skin,trunk,malignant melanoma,NS c.3251C>T p.S1084L 12
2 COSM5611082 TRRAP skin,trunk,malignant melanoma,NS c.100C>T p.P34S 12
3 COSM328254 TNC skin,trunk,malignant melanoma,NS c.1342C>G p.R448G 12
4 COSM5610746 TBX22 skin,trunk,malignant melanoma,NS c.1352G>T p.G451V 12
5 COSM5610663 SMG7 skin,trunk,malignant melanoma,NS c.2811C>T p.F937F 12
6 COSM5610425 PTPRK skin,trunk,malignant melanoma,NS c.2737G>A p.A913T 12
7 COSM5610317 PTPRD skin,trunk,malignant melanoma,NS c.2595G>A p.M865I 12
8 COSM5142 PTEN skin,trunk,malignant melanoma,NS c.112C>T p.P38S 12
9 COSM231641 PREX2 skin,trunk,malignant melanoma,NS c.1387C>T p.R463C 12
10 COSM584 NRAS skin,trunk,malignant melanoma,NS c.182A>G p.Q61R 12
11 COSM585 NRAS skin,trunk,malignant melanoma,NS c.183A>T p.Q61H 12
12 COSM571 NRAS skin,trunk,malignant melanoma,NS c.37G>A p.G13S 12
13 COSM5049808 NF1 skin,ear,malignant melanoma,NS c.3652C>T p.Q1218* 12
14 COSM5049807 NF1 skin,ear,malignant melanoma,NS c.3097C>T p.Q1033* 12
15 COSM5609545 NF1 skin,trunk,malignant melanoma,NS c.7189+1G>A p.? 12
16 COSM5609467 MTOR skin,trunk,malignant melanoma,NS c.2638A>G p.T880A 12
17 COSM5609451 MSH6 skin,trunk,malignant melanoma,NS c.4004A>G p.E1335G 12
18 COSM232755 MAP2K1 skin,trunk,malignant melanoma,NS c.607G>A p.E203K 12
19 COSM5609259 KRAS skin,trunk,malignant melanoma,NS c.130G>A p.V44I 12
20 COSM5609255 KIT skin,trunk,malignant melanoma,NS c.575G>A p.G192D 12
21 COSM5609145 IL36A skin,trunk,malignant melanoma,NS c.359C>T p.S120F 12
22 COSM109660 GRIN2A skin,ear,malignant melanoma,NS c.4097C>T p.P1366L 12
23 COSM106626 GRIN2A skin,ear,malignant melanoma,NS c.1959G>A p.M653I 12
24 COSM110485 GRIN2A skin,ear,malignant melanoma,NS c.3217G>A p.E1073K 12
25 COSM5609011 GRIN2A skin,trunk,malignant melanoma,NS c.2252G>A p.G751E 12
26 COSM5608954 GNAQ skin,trunk,malignant melanoma,NS c.264G>T p.Q88H 12
27 COSM1205523 EPHB4 skin,trunk,malignant melanoma,NS c.2177C>T p.S726L 12
28 COSM5608400 EPHA3 skin,trunk,malignant melanoma,NS c.2525G>A p.R842Q 12
29 COSM141892 CNR1 skin,ear,malignant melanoma,NS c.145C>T p.P49S 12
30 COSM141856 CHRM3 skin,ear,malignant melanoma,NS c.1741T>A p.F581I 12
31 COSM13830 CDKN2A skin,trunk,malignant melanoma,NS c.341C>A p.P114H 12
32 COSM13281 CDKN2A skin,trunk,malignant melanoma,NS c.205G>T p.E69* 12
33 COSM12503 CDKN2A skin,trunk,malignant melanoma,NS c.334C>G p.R112G 12
34 COSM478 BRAF skin,ear,malignant melanoma,NS c.1801A>G p.K601E 12
35 COSM476 BRAF skin,trunk,malignant melanoma,NS c.1799T>A p.V600E 12
36 COSM471 BRAF skin,ear,malignant melanoma,NS c.1790T>G p.L597R 12
37 COSM27639 BRAF skin,ear,malignant melanoma,NS c.1780G>A p.D594N 12
38 COSM1125 BRAF skin,ear,malignant melanoma,NS c.1790T>A p.L597Q 12
39 COSM99924 skin,trunk,malignant melanoma,NS c.856G>A p.E286K 12
40 COSM5609544 skin,trunk,malignant melanoma,NS c.7189+1G>A p.? 12
41 COSM5609546 skin,trunk,malignant melanoma,NS c.568+1G>A p.? 12
42 COSM5608955 skin,trunk,malignant melanoma,NS c.177G>T p.Q59H 12
43 COSM1176880 skin,trunk,malignant melanoma,NS c.3251C>T p.S1084L 12
44 COSM5610662 skin,trunk,malignant melanoma,NS c.2823C>T p.F941F 12
45 COSM5610316 skin,trunk,malignant melanoma,NS c.2595G>A p.M865I 12
46 COSM5610426 skin,trunk,malignant melanoma,NS c.2773G>A p.A925T 12
47 COSM5611083 skin,trunk,malignant melanoma,NS c.100C>T p.P34S 12
48 COSM231642 skin,trunk,malignant melanoma,NS c.1387C>T p.R463C 12
49 COSM5610424 skin,trunk,malignant melanoma,NS c.2737G>A p.A913T 12
50 COSM235619 skin,trunk,malignant melanoma,NS c.461C>T p.S154F 12

Expression for Skin Melanoma

Search GEO for disease gene expression data for Skin Melanoma.

Pathways for Skin Melanoma

Pathways related to Skin Melanoma according to GeneCards Suite gene sharing:

(show top 50) (show all 73)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
2
Show member pathways
13.74 BRAF CDKN1A CDKN2A CDKN2B FGF2 MDM2
3
Show member pathways
13.39 BRAF CASP3 CDKN1A FGF2 MMP2 MMP9
4
Show member pathways
12.86 CASP3 CDKN1A CDKN2A MDM2 NRAS TP53
5
Show member pathways
12.83 BRAF CASP3 NRAS PTGS2 TP53
6
Show member pathways
12.76 CDKN1A FGF2 MDM2 NRAS TP53
7 12.75 BRAF CASP3 FGF2 NRAS TP53
8 12.72 CASP3 CDKN1A FGF2 MDM2 NRAS PTGS2
9
Show member pathways
12.63 CDKN1A FGF2 MMP2 NRAS TP53
10
Show member pathways
12.61 CDKN1A CDKN2A CDKN2B MDM2 TP53
11
Show member pathways
12.56 BRAF CASP3 MDM2 NRAS TP53
12 12.55 CDKN1A CDKN2A MDM2 MLH1 TP53
13 12.48 CDKN1A CDKN2A CDKN2B NRAS TP53
14 12.48 CASP3 CDKN1A CDKN2A MDM2 MMP9 NRAS
15
Show member pathways
12.47 CASP3 MDM2 NRAS TP53
16
Show member pathways
12.42 CASP3 CDKN1A CDKN2A MDM2 TP53
17
Show member pathways
12.42 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
18
Show member pathways
12.41 CDKN1A MITF NRAS TP53 TYR
19 12.41 CDKN1A CDKN2A CDKN2B MDM2 TP53
20
Show member pathways
12.38 CDKN1A CDKN2A CDKN2B TP53
21
Show member pathways
12.36 BRAF CDKN1A MDM2 NRAS TP53
22
Show member pathways
12.3 BRAF CASP3 CDKN1A MDM2 NRAS TP53
23
Show member pathways
12.29 CASP3 CDKN1A MDM2 TP53
24 12.28 CDKN1A MDM2 MITF MMP9 TP53
25 12.28 CASP3 CDKN1A CDKN2A CDKN2B MDM2 NRAS
26
Show member pathways
12.25 BRAF CASP3 NRAS TP53
27 12.19 BRAF CASP3 MDM2 TP53
28
Show member pathways
12.18 BRAF CASP3 NRAS TP53
29
Show member pathways
12.12 BRAF CDKN1A CDKN2B MDM2 NRAS
30 12.12 BRAF CASP3 CDKN1A FGF2 MDM2 MMP2
31 12.11 BRAF CDKN1A NRAS TP53
32 12.1 CDKN1A CDKN2A MDM2 MMP2 TP53
33 12.1 CDKN1A CDKN2A MDM2 MLH1 TP53
34 12.09 CDKN1A MDM2 MLH1 MMP2 TP53
35 12.08 BRAF CASP3 CDKN1A MLH1 MMP2 MMP9
36 12.06 CASP3 MMP9 PTGS2 TP53
37 12.06 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
38 12.03 BRAF CASP3 NRAS PTGS2
39 12.03 CDKN1A FGF2 MMP2 MMP9 PTGS2 TP53
40 12.02 CDKN1A CDKN2A MDM2 NRAS TP53
41 11.98 BRAF CDKN1A CDKN2A MDM2 NRAS TP53
42 11.97 BRAF CDKN1A CDKN2A MDM2 TP53
43 11.89 FGF2 MMP2 MMP9 PTGS2
44 11.87 CDKN1A MDM2 TP53
45
Show member pathways
11.86 CDKN1A MDM2 TP53
46 11.85 CASP3 CDKN1A CDKN2B PTGS2 TP53
47
Show member pathways
11.84 BRAF CASP3 NRAS
48 11.83 CDKN1A MDM2 TP53
49 11.82 MMP9 NME1 TP53
50 11.81 MITF MMP2 MMP9

GO Terms for Skin Melanoma

Cellular components related to Skin Melanoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.5 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2

Biological processes related to Skin Melanoma according to GeneCards Suite gene sharing:

(show all 28)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.96 CASP3 CDKN2A MMP9 PTGS2 TP53
2 angiogenesis GO:0001525 9.92 FGF2 MCAM MMP2 PTGS2
3 negative regulation of cell proliferation GO:0008285 9.91 CDKN1A CDKN2A CDKN2B NME1 PTGS2 TP53
4 positive regulation of gene expression GO:0010628 9.88 BRAF MDM2 MITF TP53
5 response to drug GO:0042493 9.83 CASP3 CDKN1A MDM2 PTGS2
6 response to organic substance GO:0010033 9.81 CASP3 CDKN1A PTGS2
7 cell cycle arrest GO:0007050 9.81 CDKN1A CDKN2A CDKN2B TP53
8 protein sumoylation GO:0016925 9.8 CDKN2A MDM2 MITF
9 response to glucocorticoid GO:0051384 9.78 CASP3 CDKN1A PTGS2
10 cellular response to drug GO:0035690 9.77 BRAF NME1 TP53
11 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.77 CDKN1A MDM2 TP53
12 response to cAMP GO:0051591 9.75 BRAF NME1 TYR
13 response to UV GO:0009411 9.74 CASP3 CDKN1A TYR
14 embryo implantation GO:0007566 9.71 MMP2 MMP9 PTGS2
15 response to antibiotic GO:0046677 9.67 CASP3 MDM2 TP53
16 melanin biosynthetic process GO:0042438 9.63 PMEL TYR
17 negative regulation of fibroblast migration GO:0010764 9.63 BRAF FGF2
18 cellular response to gamma radiation GO:0071480 9.63 CDKN1A MDM2 TP53
19 response to X-ray GO:0010165 9.58 CASP3 CDKN1A TP53
20 signal transduction by p53 class mediator GO:0072331 9.55 CDKN1A TP53
21 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.54 MDM2 MMP2 MMP9
22 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.5 CASP3 CDKN1A CDKN2A
23 cellular response to actinomycin D GO:0072717 9.48 MDM2 TP53
24 negative regulation of phosphorylation GO:0042326 9.43 CDKN1A CDKN2A CDKN2B
25 negative regulation of apoptotic process GO:0043066 9.43 BRAF CASP3 CDKN1A MDM2 MMP9 TP53
26 replicative senescence GO:0090399 9.33 CDKN1A CDKN2A TP53
27 amyloid fibril formation GO:1990000 9.31 MDM2
28 Ras protein signal transduction GO:0007265 9.02 CDKN1A CDKN2A FGF2 NRAS TP53

Molecular functions related to Skin Melanoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.55 CDKN1A CDKN2A CDKN2B NME1 TP53
2 disordered domain specific binding GO:0097718 8.96 MDM2 TP53
3 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.92 CASP3 CDKN1A CDKN2A CDKN2B

Sources for Skin Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....